spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  tumor suppressor 

 HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Sep 2020
MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Aug 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Feb 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Aug 2018
Actavalon Announces Appointments of Dr. John Hood to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jun 2018
IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Biopharmaceuticals Oncology Personnel Venture Capital
 HSMN NewsFeed - 6 Oct 2016
Interpace Diagnostics Launches New Streamlined Molecular Product for Pancreatic Cysts
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 May 2016
Interpace Diagnostics Presents New Clinical Utility Data at Digestive Disease Week
Diagnostic Gastroenterology Oncology
 HSMN NewsFeed - 9 Mar 2016
Karolinska Development's Portfolio Company Aprea Raises SEK 437 Million
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Oct 2015
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2014
Aileron Therapeutics Secures $33 Million in Series E Financing to Advance Its First-In-Class Cancer Drug
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Aug 2014
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2014
Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Mar 2014
Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jan 2014
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 9 Dec 2013
LabCorp to Offer the IntelliGENTM Multi-Gene Oncology Panel on the Next Generation Sequencing Platform
Diagnostics Oncology
 HSMN NewsFeed - 20 May 2013
Karyopharm Therapeutics Raises $48.2 Million in Series B Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 10 Apr 2013
Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2013
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Oct 2012
Mirna Therapeutics Secures $34.5 Million Series C Financing to Advance Oncology microRNA Pipeline into the Clinic
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 23 Aug 2011
Mirna Therapeutics Announces Completion of Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jul 2011
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Nov 2010
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Jun 2010
Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Feb 2010
Roche Collaborates with Merck on Developmental Test for Cancer-Related Gene Mutation
Diagnostics Oncology
 HSMN NewsFeed - 12 Nov 2009
Mirna Therapeutics Appoints Dr. Paul Lammers as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2009
Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Mar 2009
Myriad Applauds New ACOG Guidelines for Hereditary Breast and Ovarian Cancer
Diagnostics Oncology
 HSMN NewsFeed - 4 Mar 2009
FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2008
Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2008
Gemin X Pharmaceuticals Appoints Peter R. Dolan to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jul 2008
Agios Pharmaceuticals Closes $33 Million Series A Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 10 Jun 2008
Senior Pharmaceutical Executive, Glenn J. Gormley, M.D., Ph.D., to Lead Gemin X Pharmaceuticals as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2008
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jan 2008
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2007
Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
Introgen's ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Nov 2007
Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the EMEA
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
Marketing Application for Vorinostat Filed in Europe for the Treatment of Advanced, Refractory Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Nov 2007
Introgen Therapeutics Highlights Summary ADVEXIN Data at the Third International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Nov 2007
Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Sep 2007
Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2007
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 25 Jun 2007
CombiMatrix Molecular Diagnostics Launches HemeScan(TM) Ploidy Test for the Management of Acute Lymphoblastic Leukemia
Diagnostics Oncology
 HSMN NewsFeed - 4 Jun 2007
Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Introgen's ADVEXIN Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2007
Celera and LabCorp(R) Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays
Diagnostics Oncology Licensing
 HSMN NewsFeed - 8 Feb 2007
Cold Spring Harbor Laboratory Scientists Discover New Gene that Prevents Multiple Types of Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2007
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
Marshall Edwards, Inc. Appoints Professor Bryan Williams as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 31 Oct 2006
Introgen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2006
TriPath Imaging Receives FDA 510(k) Clearance for p53 Application for Ventana Image Analysis System
Diagnostics Oncology FDA
 HSMN NewsFeed - 19 Sep 2006
Lorus Therapeutics announces that Dr. Jim A. Wright will step down as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical Meetings
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2006
Gendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
tumor suppressor
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!